跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 41 条关于
“monarchE”
全部
41
临床试验
18
药物
0
机构
3
资讯
20
去年
Landmark Breast Cancer Trials Reshape Treatment Paradigms for HR-positive, HER2-negative Disease
去年
Lilly's Verzenio Demonstrates Significant Overall Survival Benefit in High-Risk Early Breast Cancer
5年前
CDK4/6 Inhibitors Show Potential in HR+/HER2- Early Breast Cancer Adjuvant Therapy
5年前
CDK4/6 Inhibitors Show Trend Toward Benefit in Early Breast Cancer, Meta-Analysis Finds
去年
Optimizing Treatment Strategies in HR-Positive Breast Cancer: CDK4/6 Inhibitors, ADCs, and Personalized Approaches
去年
Ribociclib Shows Favorable Safety Profile and Maintained Efficacy with Dose Reduction in HR+ Early Breast Cancer
去年
Real-World Study Reveals 60% of Eligible Patients Not Receiving Adjuvant Abemaciclib for High-Risk Early Breast Cancer
3年前
Ribociclib Shows Promise in Broad Early Breast Cancer Population
11个月前
Bristol Myers Squibb and Lilly Showcase Major Oncology Data at ESMO 2025
去年
Novartis Highlights Scemblix and Kisqali Data at ASH and SABCS
第 1 页,共 2 页
上一页
下一页